Previous 10 | Next 10 |
PTAB turned the CRISPR industry upside down, with sleepy biotechs becoming market favorites overnight and leading companies dropping by double-digit rates. NTLA management will likely talk down the effects of the patent ruling, but given the new dynamics, this speculative trade has be...
Shares of the gene therapy specialist Bluebird Bio (NASDAQ: BLUE) are having another rough session today. Specifically, the biotech's stock is down by 11% as of 12:56 p.m. ET on Monday. Bluebird's shares are retreating today in response to two key issues: Image source: Getty...
Gainers: Clover Health Investments (NASDAQ:CLOV) +18%. Monte Rosa Therapeutics (NASDAQ:GLUE) +12%. Sharecare (NASDAQ:SHCR) +10%. InflaRx (NASDAQ:IFRX) +9%. Sigilon Therapeutics (NASDAQ:SGTX) +9%. Losers: Atreca (NASDAQ:BCEL) -30%. Biophytis (NASDAQ:BPTS) -14%. Alpine Immun...
Bluebird bio (NASDAQ:BLUE) is trading ~17% lower in the pre-market Monday after the commercial-stage biotech company announced the resignation of its Chief Financial Officer, Gina Consylman, effective Apr. 03. Consylman gave the notice of her resignation on Mar. .04, Bluebird bio (B...
Suzhou antibody company Adagene will apply its masking technology to as many as four Sanofi candidates in a collaboration worth up to $2.5 billion. Huadong Medicine will acquire Asia rights (ex-Japan) for two Heidelberg Pharma ADC candidates with options on two more in a deal potentia...
bluebird bio (NASDAQ:BLUE) is scheduled to announce Q4 earnings results on Monday, March 7th, after market close. The consensus EPS Estimate is -$1.74 (+42.2% Y/Y) and the consensus Revenue Estimate is $5.72M (-46.6% Y/Y). Over the last 1 year, BLUE has beaten EPS estimates 0% of the time and...
bluebird bio (NASDAQ:BLUE) saw its Q4 2021 net loss narrow ~22% as it posted product revenue for the first time. Its quarterly net loss was ~$155.1M, or -$2.14 per basic and diluted share. The company reported $1.4M in product revenue from its gene therapy beti-cel (betibeglogene autotemcel) ...
- The Company’s first two gene therapies, beti-cel for β-thalassemia and eli-cel for cerebral adrenoleukodystrophy, under review by the FDA - - lovo-cel BLA submission for sickle cell disease remains on track for Q1 2023 - - Ended year with $442M in r...
FBT is a passive biotechnology ETF, which doesn’t pay any dividend. Baring the past one year, FBT’s price return has outperformed the S&P 500. Effective portfolio rebalancing may determine its future growth. For further details see: FBT: A Long Term Hol...
Gainers: Clover Health Investments CLOV +21%. WM Technology MAPS +14%. bluebird bio (NASDAQ:BLUE) +7%. STAAR Surgical Company STAA +7%. MannKind Corporation MNKD +6%. Losers: Rent-A-Center RCII -31%. Pulmonx Corporation LUNG -20%. Five9 FIVN ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ:BLUE). S...
LOS ANGELES, April 30, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
LOS ANGELES, April 24, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...